Want to see CH:IDIA full AI Analyst Report?
IDIA Stock Chart & Stats
CHF6.16
CHF0.49(7.95%)
At close: 4:00 PM EDT
CHF6.16
CHF0.49(7.95%)
Day’s Range― - ―
52-Week RangeCHF2.42 - CHF7.56
Previous CloseN/A
Volume1.17M
Average Volume (3M)2.48M
Market Cap
CHF1.63B
Enterprise ValueCHF3.01K
Total Cash (Recent Filing)CHF94.70M
Total Debt (Recent Filing)CHF1.32B
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Oct 29, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding263,059,780
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF4.75Price Target Upside-22.89% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.54
Revenue Forecast (FY)CHF221.54M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~90% gross margins indicate strong product-level economics and pricing power for core medicines. Over months this supports high incremental profitability as revenue scales and can enable rapid conversion to operating leverage if SG&A/R&D growth is controlled or spreads over larger sales.
Commercial Revenue ScaleMeaningful revenue growth versus prior years shows the company has converted R&D into commercial products and can scale sales. A larger revenue base increases potential for fixed-cost absorption and more predictable cash generation assuming preservation of product uptake and reimbursement.
Partnership And Licensing ChannelsDiverse monetization via upfronts, milestones and royalties provides non-dilutive funding levers and downside protection for R&D. Structural partnerships can fund development, share commercialization burden and smooth cash volatility versus sole reliance on product sales.
Bears Say
Highly Stressed Balance SheetMaterial negative equity and heavy debt relative to assets create sustained refinancing and covenant risk, reducing strategic optionality. Over a multi-month horizon this constrains the company’s ability to fund trials, launches, or absorb setbacks without dilutive financing or onerous debt terms.
Negative Operating And Free Cash FlowRepeated cash burn implies the business requires external funding or partner financing to sustain operations. Persistent negative OCF and FCF reduce runway and increase likelihood of equity issuance or debt refinancing, which can pressure long-term investment plans and pipeline advancement.
Persistent Losses And Recent Revenue DeclineDeep, ongoing operating losses combined with a steep recent revenue drop signal that profitability depends on successful new launches or cost restructuring. Structural recovery will require either durable revenue re-acceleration or material operating expense reduction to achieve sustainable margins.
IDIA FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was CHF2.42 and its highest was CHF7.56 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF1.63B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 88 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Jul 30, 2026. The company reported -CHF0.165 earnings per share for the quarter, beating the consensus estimate of -CHF0.195 by CHF0.03.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Overvalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of N/A. See more information on Idorsia Ltd dividends here
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.27.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 263,059,780 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.165 in its last earnings report, beating expectations of -CHF0.195. Following the earnings report the stock price went down -4.962%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in CH:IDIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd (IDIA) is a Switzerland-based biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule medicines. The company’s therapeutic focus includes areas such as cardiovascular and metabolic diseases, central nervous system (CNS) disorders, and immunological/infectious-related conditions. Idorsia markets prescription medicines and continues to advance a pipeline of clinical-stage drug candidates while leveraging partnerships for development and commercialization in certain territories.
IDIA Stock 12 Month Forecast
Average Price Target
CHF4.75
▼(-22.89% Downside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―